SU788471A1 - Psychotropic agent "inkazan" for treating depressive states - Google Patents
Psychotropic agent "inkazan" for treating depressive states Download PDFInfo
- Publication number
- SU788471A1 SU788471A1 SU721850615A SU1850615A SU788471A1 SU 788471 A1 SU788471 A1 SU 788471A1 SU 721850615 A SU721850615 A SU 721850615A SU 1850615 A SU1850615 A SU 1850615A SU 788471 A1 SU788471 A1 SU 788471A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- preparations
- inkazan
- depressive states
- psychotropic agent
- treating depressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
При недостаточно выраженном лечебном эффекте инказан примен ют совместно с антидепрессантами трициклического строени , тр/анквилизаторами, нейролептиками .When the therapeutic effect is not sufficiently pronounced, Incas is used together with antidepressants of tricyclic structure, tr / anquilizers, and neuroleptics.
Препарат не следует назначать во второй половине дн , так как он может вызвать ухудшение сна.The drug should not be prescribed in the second half of the day, as it can cause deterioration of sleep.
Предл/агаемое средство эффективно при лечении депрессивных состо ний, хорошо переноситс организмом и может найти широкое применение не только в стационаре , но и в амбулаторных услови х.The proposed agent is effective in the treatment of depressive conditions, is well tolerated by the body and can be widely used not only in the hospital, but also in outpatient conditions.
Claims (1)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU721850615A SU788471A1 (en) | 1972-11-28 | 1972-11-28 | Psychotropic agent "inkazan" for treating depressive states |
DE2356091A DE2356091A1 (en) | 1972-11-28 | 1973-11-09 | MEDICINAL PRODUCTS WITH PSYCHOTROPIC EFFECT |
GB5522473A GB1444980A (en) | 1972-11-28 | 1973-11-28 | Psychotropic medicinal preparation |
FR7342414A FR2207727B1 (en) | 1972-11-28 | 1973-11-28 | |
US05/557,189 US3959470A (en) | 1972-11-28 | 1975-03-10 | Psychotropic medicinal preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU721850615A SU788471A1 (en) | 1972-11-28 | 1972-11-28 | Psychotropic agent "inkazan" for treating depressive states |
Publications (1)
Publication Number | Publication Date |
---|---|
SU788471A1 true SU788471A1 (en) | 1981-12-30 |
Family
ID=20533240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU721850615A SU788471A1 (en) | 1972-11-28 | 1972-11-28 | Psychotropic agent "inkazan" for treating depressive states |
Country Status (4)
Country | Link |
---|---|
DE (1) | DE2356091A1 (en) |
FR (1) | FR2207727B1 (en) |
GB (1) | GB1444980A (en) |
SU (1) | SU788471A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1637521B1 (en) | 2003-06-23 | 2013-06-19 | Ono Pharmaceutical Co., Ltd. | Novel tricyclic heterocycle compound |
EP1829874B1 (en) | 2004-12-22 | 2014-02-12 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
-
1972
- 1972-11-28 SU SU721850615A patent/SU788471A1/en active
-
1973
- 1973-11-09 DE DE2356091A patent/DE2356091A1/en active Pending
- 1973-11-28 GB GB5522473A patent/GB1444980A/en not_active Expired
- 1973-11-28 FR FR7342414A patent/FR2207727B1/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
GB1444980A (en) | 1976-08-04 |
FR2207727A1 (en) | 1974-06-21 |
FR2207727B1 (en) | 1977-09-02 |
DE2356091A1 (en) | 1974-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meyer et al. | The antirheumatic effect of sodium gentisate | |
IT9020562A1 (en) | ANTITUSSIVE AGENT AND MUCOREGULATOR, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS | |
SU788471A1 (en) | Psychotropic agent "inkazan" for treating depressive states | |
GB1503675A (en) | Compositions based on pyrimidine derivatives and their use in the treatment of viral infections | |
Buscaglia et al. | Pulmonary infiltrates associated with naproxen | |
Bowers et al. | Central monoamine oxidase inhibition and REM sleep. | |
Lusch et al. | Antipyretic effect of indomethacin in patients with malignancy | |
GB1018117A (en) | ||
GB1291559A (en) | N-(4-chlorocinnamoyl)-4-hydroxypiperidine | |
SCHAEFER et al. | Sodium gentisate in the treatment of acute rheumatic fever | |
GB1154454A (en) | New Anthranilic Acid Derivatives | |
Barowsky et al. | A new approach to the management of peptic ulcer by inducing sustained gastric inactivity. | |
GB1415228A (en) | Pharmacologically active acetic acid derivatives | |
BUNTING et al. | Toxic Reactions of Sulfaguanidine Therapy | |
SU459228A1 (en) | Medicine | |
Komurcugil et al. | A Case of Steven-Johnson Syndrome: Favipiravir induced or Covid-19 disease related? | |
BE800284A (en) | Indan carboxylic acid derivs compsns - for treatment of allergies | |
GB1327468A (en) | Pharmaceutical compositions for inhibiting indoleamine n-methyl transferase | |
McCleave | Dysmenorrhea | |
Guest et al. | Acute endocarditis due to Staphylococcus aureus successfully treated with penicillin | |
SOUTHWORTH | Subacute staphylococcus endocarditis and staphylococcus bacteremia without endocarditis with a report of the favorable effect of sulfanilamide and sulfathiazole in two cases | |
KANTER et al. | Treatment of dermatitis herpetiformis resistant to usual therapy | |
SE329398B (en) | ||
SU1261670A1 (en) | Method of treatment of patients ill with chronic furunculosis | |
Chatterjee et al. | Possible Therapeutic Value of Drug Induced Side Reactions |